Showing 1 - 20 results of 24 for search '"смешанная криоглобулинемия"', query time: 0.62s Refine Results
  1. 1
    Academic Journal

    Source: Aktualʹnaâ Infektologiâ, Vol 4, Iss 3.12, Pp 52-56 (2016)
    ACTUAL INFECTOLOGY; № 3.12 (2016); 52-56
    Актуальная инфектология-Aktualʹnaâ Infektologiâ; № 3.12 (2016); 52-56
    Актуальна інфектологія-Aktualʹnaâ Infektologiâ; № 3.12 (2016); 52-56

    File Description: application/pdf

  2. 2
  3. 3
    Academic Journal

    Source: Meditsinskiy sovet = Medical Council; № 21 (2019); 248-253 ; Медицинский Совет; № 21 (2019); 248-253 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-21

    File Description: application/pdf

    Relation: https://www.med-sovet.pro/jour/article/view/5501/5020; Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–171. doi:10.1016/S0140-6736(14)61682-2.; Lee M.H., Yang H.I., Lu S.N., Jen C.L., You S.L., Wang L.Y., et al. Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J. Infect.Dis. 2012;206(4):469–477. doi:10.1093/infdis/jis385.; Younossi Z., Park H., Henry L., Adeyemi A., Stepanova M. Extrahepatic manifestations of hepatitis C: a meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599–1608. doi:10.1053/j.gastro.2016.02.039.; Monaco S., Mariotto S., Ferrari S., Calabrese M., Zanusso G., Gajofatto A., et al. Hepatitis C virusassociated neurocognitive and neuropsychiatric disorders: Advances in 2015. World Journal of Gastroenterology. 2015;21(42):11974–11983. doi:10.3748/wjg.v21.i42.11974.; Byrnes V., Miller A., Lowry D., Hill E., Weinstein C., Alsop D., et al. Effects of anti-viral therapy and HCV clearance on cerebral metabolism and cognition. Journal of Hepatology. 2012;56(3):549–556. doi:10.1016/j.jhep.2011.09.015.; Morgello S., Murray J., Van Der Elst S., Byrd D. HCV, but not HIV, is a risk factor for cerebral small vessel disease. Neurology: Neuroimmuno logy&Neuroinflammation. 2014;1(3):e27. doi:10.1212/NXI.0000000000000027.; Enger C., Forssen U.M., Bennett D., Theodore D., Shantakumar S., McAfee A. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Advances in Therapy. 2014;31(8):891–903. doi:10.1007/s12325-014-0138-4.; Liao C.C., Su T.C., Sung F.C., Chou W.H., Chen T.L. Does hepatitis C virus infection increase risk for stroke? A population-based cohort study. PLoS ONE. 2012;7(2):e31527. doi:10.1371/journal.pone.0031527.; Huang H., Kang R., Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS ONE. 2013;8(11):e81305. doi:10.1371/journal.pone.0081305.; Wong R.J., Gish R.G. Metabolic manifestations and complications associated with chronic hepatitis C virus infection. Gastroenterology and Hepatology. 2016;12(5):293–299. Available at: https://www.gastroenterologyandhepatology.net/archives/may-2016/metabolic-manifestations-and-complications-associated-withchronic-hepatitis-c-virus-infection/; Naing C., Mak J.W., Ahmed S.I., Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: meta-analysis. World Journal of Gastroenterology. 2012;18(14):1642–1651. doi:10.3748/wjg.v18.i14.1642.; Chandra P.K., Hazari S., Poat B., Gunduz F., Prabhu R., Liu G., et al. Intracytoplasmic stable expression of IgG1 antibody targeting NS3 helicase inhibits replication of highly efficient hepatitis C Virus 2a clone. Virol. J. 2010;7:118. doi:10.1186/1743-422X-7-118.; Ostojic P., Jeremic I.R. Managing refractory cryoglobulinemic vasculitis: challenges and solutions. Journal of Inflammation Research. 2017;10:49–54. doi:10.2147/JIR.S114067.; Cacoub P., Comarmond C., Domont F., Savey L., Desbois A.C., Saadoun D. Extrahepatic manifestation of chronic hepatitis C virus infection. Therapeutic Advances in Infectious Disease. 2016;3(1):3–14. doi:10.1177/2049936115585942.; Стельмах В.В., Козлов В.К., Суханов Д.С., Скипский И.М. Васкулит легких как клиниче- ская «маска» HCV-инфекции: эффективность безинтерфероновой противовирусной тера- пии. Терапевтический архив. 2014;11:87–92. Режим доступа: https://www.mediasphera.ru/issues/terapevticheskij-arkh; iv/2014/11/030040-366020141117. Stel’mah V.V., Kozlov V.K., Sukhanov D.S., Skipskij I.M. Pulmonary vasculitis as a clinical mask of HCV infection: Efficiency of interferon-free antiviral therapy. Therapeutic archive = Terapevticheskiy arkhiv. 2014;11:87–92. (In Russ.) Available at: https://www.mediasphera.ru/issues/terapevticheskij-arkhiv/2014/11/030040-366020141117.; Retamozo S., Díaz-Lagares C., Bosch X., Bové A., Brito-Zerón P., Gómez M.E., et al. Life- threatening cryoglobulinemic patients with hepatitis C: clinical description and outcome of 279 patients. Medicine. 2013;92(5):273–284. doi:10.1097/MD.0b013e3182a5cf71.; Terrier B., Cacoub P. Renal involvement in HCV-related vasculitis. Clin. Res. Hepatol. Gastroenterol. 2013;37(4):334–339. doi:10.1016/j.clinre.2013.02.002; Tang L., Marcell L., Kottilil S. Systemic manifestations of hepatitis C infection. Infectious Agents and Cancer. 2016;11:29. doi:10.1186/s13027-016-0076-7.; Perico N., Cattaneo D., Bikbov B., Remuzzi G. Hepatitis C infection and chronic renal diseases. Clin. J. Amer. Soc. Nephrol. 2009;4(1):207–220. doi:10.2215/CJN.03710708.; Fabrizi F., Verdesca S., Messa P., Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: A systematic review and meta-analysis. Digestive Diseases and Sciences. 2015;60(12):3801–3813. doi:10.1007/s10620-015-3801-y.; Fabrizi F., Dixit V., Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? J Viral Hepat. 2012;19(9):601–607. doi:10.1111/j.1365-2893.2012.01633.x.; Shen Y., Wang X.L., Xie J.P., Shao J.G., Lu Y.H., Zhang S., Qin G. Thyroid disturbance in patients with chronic hepatitis C infection: a systematic review and meta-analysis. Journal of gastrointestinal and liver diseases. 2016;25(2):227–234. doi:10.15403/jgld.2014.1121.252.chc.; Blackard J.T., Kong L., Huber A.K., Tomer Y. Hepatitis C virus infection of a thyroid cell line: implications for pathogenesis of HCV and thyroiditis analysis. Thyroid. 2013;23(7):863–870. doi:10.1089/thy.2012.0507.; Raphael B.A., Dorey-Stein Z.L, Lott J., Amorosa V., Lo Re V 3rd, Kovarik C. Low prevalence of necrolytic acral erythema in patients with chronic hepatitis C virus infection. J Am Acad Dermatol. 2012;67(5):962–968. doi:10.1016/j.jaad.2011.11.963.; Moneib H.A.M., Salem S.A.M., Darwish M.M. Evaluation of zinc level in skin of patients with necrolytic acral erythema. Br J Dermatol. 2010;163(3):476–480. doi:10.1111/j.1365-2133.2010.09820.x.; Raslan H.M., Ezzat W.M., Abd El Hamid M.F., Emam H., Amre K.S. Skin manifestationsof chronic hepatitis C virus infection in Cairo, Egypt. East Mediterr Health J. 2009;15(3):692–700. Available at: http://www.emro.who.int/emhj-volume-15-2009/volume-15-issue-3/skin-manifestations-of-chronic-hepatitis-cvirus-infection-in-cairo-egypt.html.; Petti S., Rabiei M., De Luca M., Scully C. The magnitude of the association between hepatitis C virus infection and oral lichen planus: meta-analysis and case control study. Odontology. 2011;99(2):168–178. doi:10.1007/s10266-011-0008-3.; Pothineni N.V., Delongchamp R., Vallurupalli S., Ding Z., Dai Y., Hagedorn C.H., Mehta J.L. Impact of hepatitis C seropositivity on the risk of coronary heart disease events. American Journal of Cardiology. 2014;114(12):1841–1845. doi:10.1016/j.amjcard.2014.09.020.; Gill K., Ghazinian H., Manch R., Gish R. Hepatitis C virus as a systemic disease: Reaching beyond the liver. Hepatology International. 2016;10(3):415–423. doi:10.1007/s12072-015-9684-3.; Hsu Y.C., Ho H.J., Huang Y.T., Wang H.H., Wu M.S., Lin J.T., Wu C.Y. Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection. Gut. 2015;64(3):495–503. doi:10.1136/gutjnl-2014-308163.; Domont F., Cacoub P. Chronic hepatitis C virus infection, a new cardiovascular risk factor? Liver International. 2016;36(5):621–627. Available at: https://www.ncbi.nlm.nih.gov/pubmed/26763484.; Huang H., Kang R., Zhao Z. Is hepatitis C associated with atherosclerotic burden? A systematic review and meta-analysis. PLoS ONE. 2014;9(9):e106376. doi:10.1371/journal.pone.0106376.; Adinolfi L.E., Zampino R., Restivo L., Lonardo A., Guerrera B., Marrone A., et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World Journal of Gastroenterology. 2014;20(13):3410–3417. doi:10.3748/wjg.v20.i13.3410.; Boddi M., Abbate R., Chellini B., Giusti B., Giannini C., Pratesi G., et al. Hepatitis C virus RNA localization in human carotid plaques. Journal of Clinical Virology. 2010;47(1):72–75. doi:10.1016/j.jcv.2009.10.005

  4. 4
    Academic Journal

    Source: Pathologia; Vol. 16 No. 1 (2019): Pathologia ; Патология; Том 16 № 1 (2019): Патологія ; Патологія; Том 16 № 1 (2019): Патологія ; 2310-1237 ; 2306-8027

    File Description: application/pdf

  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
    Academic Journal

    Source: Zaporožskij Medicinskij Žurnal, Iss 6, Pp 14-16 (2012)
    Zaporozhye Medical Journal; № 6 (2012)
    Запорожский медицинский журнал; № 6 (2012): Запорожский медицинский журнал
    Запорожский медицинский журнал; № 6 (2012)

    File Description: application/pdf

  19. 19
    Academic Journal

    Source: Буковинський медичний вісник; Том 16, № 3 (63) p.1 (2012); 80-83
    Буковинский медицинский вестник; Том 16, № 3 (63) p.1 (2012); 80-83
    Bukovinian Medical Herald; Том 16, № 3 (63) p.1 (2012); 80-83

    File Description: application/pdf

  20. 20